Product image of Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202) supplied by GNH India

Influvac Tetra

Active Ingredient:
B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202
Origin:
EU

Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

B/Phuket/3073/2013‑Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is intended to prevent influenza infection caused by the virus strains included in the vaccine, primarily in individuals aged six months and older.

GNH India supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Healthcare Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Influvac Tetra is a quadrivalent influenza vaccine used to prevent seasonal influenza caused by the four virus strains it contains.

  • Seasonal influenza: reduces the risk of infection with the four influenza virus strains included in the vaccine.
  • Children ≥6 months: provides active immunity against circulating influenza B strains.
  • Adults and elderly: helps prevent influenza‑related complications and hospitalisation.
  • High‑risk groups (e.g., chronic disease patients): lowers the likelihood of severe flu outcomes.
  • Healthcare workers: contributes to occupational health by reducing transmission risk.

How It Works

  • Influvac Tetra induces active immunity by presenting hemagglutinin and neuraminidase antigens from the four selected influenza virus strains to the immune system. This stimulates B‑cell production of strain‑specific antibodies and activates T‑cell responses, resulting in protective immunity that neutralises the virus upon exposure.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Low‑grade fever: transient temperature rise within 24‑48 hours.
  • Headache or malaise: general feeling of tiredness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder potentially triggered post‑vaccination.
  • High fever or seizures: especially in young children.
  • Myocarditis or pericarditis: inflammation of heart muscle or surrounding tissue.

Precautions & Warnings

Influvac Tetra should be administered with consideration of the following precautions.

  • Allergy assessment: avoid if known severe allergy to any vaccine component.
  • Prior severe reaction: defer vaccination in individuals who experienced a serious adverse event after a previous influenza vaccine.
  • Immunocompromised patients: vaccine may elicit a reduced immune response; consult healthcare provider.
  • Pregnancy: use only if the potential benefits outweigh uncertain risks, as safety data are limited.
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Influvac Tetra has limited known drug interactions, but certain co‑administered therapies may affect its efficacy.

Major Interactions (Avoid)

  • None identified: no known drug interactions requiring avoidance.

Moderate Interactions (Monitor Closely)

  • Concurrent immunoglobulin therapy: may reduce vaccine immunogenicity; consider timing separation.
  • Antipyretics before vaccination: may blunt antibody response; use after vaccination if needed.
  • Live attenuated vaccines given within 4 weeks: monitor for potential immune interference.

Frequently Asked Questions

Influvac Tetra is a quadrivalent influenza vaccine designed to protect against seasonal flu caused by four specific influenza virus strains. It is administered to individuals six months of age and older to reduce the risk of infection, complications, and transmission of influenza.

The vaccine contains inactivated virus antigens that mimic the hemagglutinin and neuraminidase proteins of the targeted influenza strains. When injected, these antigens stimulate the immune system to produce specific antibodies and cellular responses, establishing immunity that can neutralise the real virus if encountered.

The prescribed dose of Influvac Tetra is determined by the treating healthcare professional based on age, health status, and local immunisation guidelines. Typically, a single intramuscular or subcutaneous injection is given each influenza season, but the exact regimen should be confirmed by the prescriber.

Safety data for Influvac Tetra in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It may be administered if the potential benefits outweigh any theoretical risks. Breastfeeding is not contraindicated, but mothers should discuss vaccination with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Influvac Tetra is a quadrivalent, inactivated vaccine covering two influenza A subtypes and two B lineages, offering broader protection than trivalent formulations. Compared with live‑attenuated nasal sprays, it is administered via injection and is suitable for a wider range of ages, including immunocompromised individuals.

The vaccine must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. It should be kept in the original packaging until use to maintain potency and stability throughout the supply chain.

Influvac Tetra is supplied as a sterile injectable solution. It is given as a single intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm or the anterolateral thigh in young children, by a qualified healthcare professional.

The most serious adverse events reported are severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and rare cases of high fever or seizures, particularly in children. Immediate medical attention is required if any signs of a serious reaction appear after vaccination.

Individuals with a known severe allergy to any component of the vaccine, or those who have experienced a serious adverse reaction to a previous influenza vaccine, should not receive Influvac Tetra. Consultation with a healthcare provider is essential for anyone with uncertain medical history.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT